Published in Diabetes on December 01, 2002
Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res (2007) 3.67
Inflammation in diabetic retinopathy. Prog Retin Eye Res (2011) 3.29
Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol (2008) 2.26
A specific and sensitive assay for blood levels of glycated CD59: a novel biomarker for diabetes. Am J Hematol (2013) 1.44
The role of complement system in ocular diseases including uveitis and macular degeneration. Mol Immunol (2007) 1.37
The polyol pathway as a mechanism for diabetic retinopathy: attractive, elusive, and resilient. Exp Diabetes Res (2007) 1.35
Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ Res (2009) 1.23
The transforming growth factor-beta pathway is a common target of drugs that prevent experimental diabetic retinopathy. Diabetes (2009) 1.11
Comparison of three strains of diabetic rats with respect to the rate at which retinopathy and tactile allodynia develop. Mol Vis (2010) 0.97
Complement C3: an emerging risk factor in cardiometabolic disease. Diabetologia (2012) 0.91
Proteomic analysis of human vitreous humor. Clin Proteomics (2014) 0.90
Gene expression differences in skin fibroblasts in identical twins discordant for type 1 diabetes. Diabetes (2012) 0.89
Correlation of complement fragment C5a with inflammatory cytokines in the vitreous of patients with proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2012) 0.85
Association of CFH and CFB gene polymorphisms with retinopathy in type 2 diabetic patients. Mediators Inflamm (2013) 0.85
Complement regulatory protein CD46 protects against choroidal neovascularization in mice. Am J Pathol (2014) 0.83
Role of complement and complement regulatory proteins in the complications of diabetes. Endocr Rev (2015) 0.82
Elevated properdin and enhanced complement activation in first-degree relatives of South Asian subjects with type 2 diabetes. Diabetes Care (2012) 0.82
Modulation of retinal Müller cells by complement receptor C5aR. Invest Ophthalmol Vis Sci (2013) 0.81
Protective effects of astragaloside IV on db/db mice with diabetic retinopathy. PLoS One (2014) 0.81
Antibody-mediated retinal pericyte injury: implications for diabetic retinopathy. Invest Ophthalmol Vis Sci (2012) 0.80
Adeno-associated virus mediated delivery of a non-membrane targeted human soluble CD59 attenuates some aspects of diabetic retinopathy in mice. PLoS One (2013) 0.80
Retinal and nonocular abnormalities in Cyp27a1(-/-)Cyp46a1(-/-) mice with dysfunctional metabolism of cholesterol. Am J Pathol (2014) 0.79
Targeting the complement system for the management of retinal inflammatory and degenerative diseases. Eur J Pharmacol (2016) 0.78
Drosophila GPI-mannosyltransferase 2 is required for GPI anchor attachment and surface expression of chaoptin. Vis Neurosci (2012) 0.78
Single injection of triamcinolone versus three repeated injections of bevacizumab for treatment of diabetic macular edema. Int Ophthalmol (2013) 0.77
Genetic Investigation of Complement Pathway Genes in Type 2 Diabetic Retinopathy: An Inflammatory Perspective. Mediators Inflamm (2016) 0.76
Presence of retinal pericyte-reactive autoantibodies in diabetic retinopathy patients. Sci Rep (2016) 0.75
Glycation of the complement regulatory protein CD59 is a novel biomarker for glucose handling in humans. J Clin Endocrinol Metab (2014) 0.75
Soluble CD59 is a Novel Biomarker for the Prediction of Obstructive Chronic Lung Allograft Dysfunction After Lung Transplantation. Sci Rep (2016) 0.75
Multiple knockout mouse models reveal lincRNAs are required for life and brain development. Elife (2013) 2.66
Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes (2002) 2.05
A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes (2003) 1.61
Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes (2004) 1.35
Retinal vascular caliber as a biomarker for diabetes microvascular complications. Diabetes Care (2013) 1.32
The transforming growth factor-beta pathway is a common target of drugs that prevent experimental diabetic retinopathy. Diabetes (2009) 1.11
A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes (2006) 1.03
IL-1β is upregulated in the diabetic retina and retinal vessels: cell-specific effect of high glucose and IL-1β autostimulation. PLoS One (2012) 1.00
Aspirin at low-intermediate concentrations protects retinal vessels in experimental diabetic retinopathy through non-platelet-mediated effects. Diabetes (2005) 0.93
Spatiotemporal expression and transcriptional perturbations by long noncoding RNAs in the mouse brain. Proc Natl Acad Sci U S A (2015) 0.91
Decreased cerebrovascular brain-derived neurotrophic factor-mediated neuroprotection in the diabetic brain. Diabetes (2011) 0.90
Endothelial progenitor cells carrying monocyte markers are selectively abnormal in type 1 diabetic patients with early retinopathy. Diabetes (2012) 0.83
Tumor angiogenesis. N Engl J Med (2008) 0.82
Endothelial progenitor cells and response to ranibizumab in age-related macular degeneration. Retina (2014) 0.75
Macular micropseudocysts in early stages of diabetic retinopathy. Retina (2011) 0.75